EMBC250117P12500
- 0.15
- 0.000.00%
Embecta Newsroom
The Zacks Analyst Blog Highlights Doximity, BrightSpring Health Services and Embecta
3 Stocks Trading Near 52-Week High With Room to Rise Further
Fluctuations are expected to continue in the early days of Trump's presidency, with Citigroup favoring Medical, Financial, and other defensive Industries.
In the market volatility and uncertainty following Trump's inauguration, defensive industries such as Medical Care and finance are favored in the model portfolio created by Citigroup strategists.
Zacks.com Featured Highlights Include The Gap, Embecta, Blue Bird and ZIM Integrated Shipping Services
Embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Embecta | 10-K: FY2024 Annual Report
BTIG Maintains Embecta(EMBC.US) With Buy Rating, Maintains Target Price $26
BTIG Upgrades Embecta Corporation (EMBC) to a Buy
Embecta To Go Ex-Dividend On December 6th, 2024 With 0.15 USD Dividend Per Share
December 4th (Eastern Time) - $Embecta(EMBC.US)$ is trading ex-dividend on December 6th, 2024.Shareholders of record on December 6th, 2024 will receive 0.15 USD dividend per share on December 18th, 20
Embecta Corp Appoints Anthony Roth as VP and CAO
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley Upgrades Embecta to Equalweight, Price Target Is $20
Is It Time To Consider Buying Embecta Corp. (NASDAQ:EMBC)?
This Dick's Sporting Goods Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Embecta Raised to Buy From Neutral by BTIG
Embecta Price Target Announced at $26.00/Share by BTIG
Embecta Analyst Ratings
BTIG Upgrades Embecta(EMBC.US) to Buy Rating, Announces Target Price $26
Morgan Stanley Maintains Embecta(EMBC.US) With Sell Rating, Maintains Target Price $13